Noven Appoints Michael D. Price Chief Financial Officer

Succeeds Diane M. Barrett, Who is Retiring After Seven Years of Service

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the appointment of Michael D. Price as vice president and chief financial officer, effective November 19, 2007, succeeding Diane M. Barrett, who is retiring at year-end.

“Michael brings to Noven a diverse financial and business planning background as well as an extensive knowledge of the pharmaceutical industry,” said Robert C. Strauss, Noven’s President, CEO & Chairman. “His broad financial experience includes strategic planning, mergers and acquisitions, capital markets, Sarbanes-Oxley compliance, financial reporting, internal controls and procedures and risk management. We believe this impressive skill set will serve us well as we continue to integrate the operations of our recent acquisition and advance our growth initiatives for 2008 and beyond.”

“On behalf of the company and the entire board of directors, I would like to thank Diane for her many contributions across the Noven organization” continued Strauss. “Diane has agreed to assist our financial team through the end of this year, assuring a smooth transition.”

Price, 50, comes to Noven with 25 years of experience as a financial executive. From 1992 to 2006, he was employed by Bentley Pharmaceuticals, Inc., a New York Stock Exchange listed specialty pharmaceuticals company, where he served as vice president, chief financial officer, treasurer and secretary. During nine years of his tenure at Bentley, he also acted as a member of that company’s board of directors. Earlier in his career, Price served as a senior executive with Carr Financial Group, and as vice president – finance with Premiere Group, Inc.

A certified public accountant, Price began his career at PricewaterhouseCoopers. He earned a Master of Business Administration degree from Florida State University and a Bachelor of Science degree in Business Administration – accounting from Auburn University.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, has established itself as a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Its commercialized transdermal products include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD.

With the acquisition of JDS Pharmaceuticals in August 2007, Noven has become a broader-based specialty pharmaceutical company with a substantially enhanced late-stage product pipeline and the infrastructure, products and category expertise to market and sell its own products.

Products currently marketed through the Noven/JDS sales infrastructure consist of Pexeva® (paroxetine mesylate) and Lithobid® (lithium carbonate). Developmental products in psychiatry consist of Stavzor™ (delayed release valproic acid softgel), Lithium QD (once-daily lithium carbonate), and Stavzor™ ER (extended release valproic acid softgel). The development pipeline in women’s health consists of Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product entering Phase 3 clinical trials for vasomotor symptoms (hot flashes).

See for additional information.

Joseph C. Jones
Vice President – Corporate Affairs